shutterstock-36383392

NICK BIEMANS / SHUTTERSTOCK.COM

9 June 2016AsiaArchana Shanker

The battle for biotech drugs in India

The Indian biologic market is growing at an annual rate of around 30%. India is therefore seen as a key player in the biosimilar space with an exceptionally high number of approvals granted in the last decade compared to the global average.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Gene tech firm fends off injunction in test kit dispute

Comparing life sciences IP in Brazil and the US

EPO invalidates human milk patent after Nestle opposition

Bayer gains exclusive licence for heart drug in Japan

UPC bans Meril Life Sciences from selling infringing heart valve

GSK triumphs in EPO appeal, revoking Pfizer patent

‘We took Ravgen head-on’: How we won zero-damages and others didn't

White & Case hires experienced litigator from A&O Shearman